Diaceutics PLC (AIM:DXRX)
London
· Delayed Price · Currency is GBP · Price in GBX 118.50
+0.98 (0.83%)
Jun 27, 2025, 4:35 PM GMT+1
Diaceutics Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 32.16 | 23.7 | 19.5 | 13.94 | 12.7 | Upgrade
|
| Revenue Growth (YoY) | 35.69% | 21.51% | 39.88% | 9.82% | -5.55% | Upgrade
|
| Cost of Revenue | 3.89 | 3.99 | 2.76 | 1.71 | 3.23 | Upgrade
|
| Gross Profit | 28.27 | 19.71 | 16.74 | 12.23 | 9.46 | Upgrade
|
| Selling, General & Admin | 30.74 | 22.78 | 16.28 | 11.88 | 10.02 | Upgrade
|
| Other Operating Expenses | -0.02 | -0.06 | -0.11 | -0.2 | -0.28 | Upgrade
|
| Operating Expenses | 30.73 | 22.72 | 16.17 | 11.68 | 9.73 | Upgrade
|
| Operating Income | -2.46 | -3.02 | 0.58 | 0.55 | -0.27 | Upgrade
|
| Interest Expense | -0.05 | -0.07 | -0.12 | -0.09 | -0.05 | Upgrade
|
| Interest & Investment Income | 0.6 | 0.65 | 0.11 | - | 0.03 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | -0 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -1.91 | -2.44 | 0.56 | 0.46 | -0.29 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | -0.39 | Upgrade
|
| Pretax Income | -1.91 | -2.44 | 0.56 | 0.46 | -0.68 | Upgrade
|
| Income Tax Expense | -0.21 | -0.69 | -0.16 | -0.1 | -0.95 | Upgrade
|
| Net Income | -1.7 | -1.75 | 0.72 | 0.56 | 0.26 | Upgrade
|
| Net Income to Common | -1.7 | -1.75 | 0.72 | 0.56 | 0.26 | Upgrade
|
| Net Income Growth | - | - | 29.05% | 113.31% | -33.92% | Upgrade
|
| Shares Outstanding (Basic) | 84 | 84 | 84 | 84 | 78 | Upgrade
|
| Shares Outstanding (Diluted) | 84 | 84 | 86 | 85 | 78 | Upgrade
|
| Shares Change (YoY) | 0.27% | -2.16% | 1.35% | 9.14% | 21.29% | Upgrade
|
| EPS (Basic) | -0.02 | -0.02 | 0.01 | 0.01 | 0.00 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.02 | 0.01 | 0.01 | 0.00 | Upgrade
|
| EPS Growth | - | - | 27.29% | 94.55% | -45.29% | Upgrade
|
| Free Cash Flow | 0.55 | 1.19 | 4.91 | 0.01 | 0.12 | Upgrade
|
| Free Cash Flow Per Share | 0.01 | 0.01 | 0.06 | - | 0.00 | Upgrade
|
| Gross Margin | 87.91% | 83.15% | 85.83% | 87.73% | 74.53% | Upgrade
|
| Operating Margin | -7.63% | -12.73% | 2.95% | 3.94% | -2.13% | Upgrade
|
| Profit Margin | -5.30% | -7.37% | 3.71% | 4.02% | 2.07% | Upgrade
|
| Free Cash Flow Margin | 1.71% | 5.00% | 25.17% | 0.04% | 0.91% | Upgrade
|
| EBITDA | 0.55 | 0.1 | 2.08 | 1.52 | 0.43 | Upgrade
|
| EBITDA Margin | 1.72% | 0.43% | 10.64% | 10.88% | 3.35% | Upgrade
|
| D&A For EBITDA | 3.01 | 3.12 | 1.5 | 0.97 | 0.7 | Upgrade
|
| EBIT | -2.46 | -3.02 | 0.58 | 0.55 | -0.27 | Upgrade
|
| EBIT Margin | -7.63% | -12.73% | 2.95% | 3.94% | -2.13% | Upgrade
|
Updated Sep 17, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.